These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Gisselbrecht C; Vose J; Nademanee A; Gianni AM; Nagler A Oncologist; 2009; 14 Suppl 2():41-51. PubMed ID: 19819923 [TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
6. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016 [TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of non-Hodgkin's lymphomas. Cheson BD Curr Drug Targets; 2006 Oct; 7(10):1293-300. PubMed ID: 17073591 [TBL] [Abstract][Full Text] [Related]
8. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Santos ES; Kharfan-Dabaja MA; Ayala E; Raez LE Leuk Lymphoma; 2006 Dec; 47(12):2453-76. PubMed ID: 17169792 [TBL] [Abstract][Full Text] [Related]
9. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL). Bischof Delaloye A Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740 [TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy for B-cell non-hodgkin lymphomas. Tomblyn M Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895 [TBL] [Abstract][Full Text] [Related]
11. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Morschhauser F; Dreyling M; Rohatiner A; Hagemeister F; Bischof Delaloye A Oncologist; 2009; 14 Suppl 2():17-29. PubMed ID: 19819921 [TBL] [Abstract][Full Text] [Related]
12. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Borghaei H; Wallace SG; Schilder RJ Clin Lymphoma; 2004 Oct; 5 Suppl 1():S16-21. PubMed ID: 15498145 [TBL] [Abstract][Full Text] [Related]
13. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. Gregory SA; Hohloch K; Gisselbrecht C; Tobinai K; Dreyling M Oncologist; 2009; 14 Suppl 2():4-16. PubMed ID: 19819920 [TBL] [Abstract][Full Text] [Related]
14. Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. Multani P Int J Hematol; 2002 Dec; 76(5):401-10. PubMed ID: 12512834 [TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma. Macklis RM Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564 [TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. Alcindor T; Witzig TE Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764 [TBL] [Abstract][Full Text] [Related]